Quantcast
Last updated on April 17, 2014 at 11:16 EDT

Latest Trovagene Inc. Stories

2013-09-04 04:21:22

Rodman & Renshaw 15th Annual Global Healthcare Conference and Stifel Healthcare Conference 2013 SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2013 healthcare conferences: Rodman & Renshaw and Stifel. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) Rodman &...

2013-08-14 16:26:07

SAN DIEGO, Aug. 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and the six months ended June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) Second Quarter 2013 Financial Results For the three months ended June 30, 2013, Trovagene reported a net loss of $5.3 million, or $0.34 per share, as compared to a net loss of $3.4 million, or $0.28 per share, for...

2013-07-31 04:21:04

SAN DIEGO, July 31, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has closed a registered direct offering of $15 million of common stock at a price of $7.00 per share. The shares were sold directly to an institutional investor by the Company. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) Trovagene intends to use the net proceeds from the offering to fund its research and development...

2013-07-29 04:21:26

Digital PCR system adoption helps create ultra-sensitive cell-free DNA assay SAN DIEGO and BILLERICA, Mass., July 29, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) and RainDance Technologies announced today that Trovagene has adopted RainDance's RainDrop(TM) Digital PCR System for research and development, and for eventual use in the Trovagene CLIA laboratory. Trovagene has also announced successful development of a cell-free DNA mutation assay leveraging the RainDrop...

2013-07-24 04:22:21

Patent covers methods of detecting cell-free microRNA in urine and blood SAN DIEGO, July 24, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced the issuance of US patent 8,486,626, "Methods of detecting cell-free miRNA in urine and blood." The patent pertains to the detection and quantitation of microRNA (miRNA) using a wide variety of technologies and platforms. MicroRNAs are known to play critical roles in cell development...

2013-07-22 04:20:48

Trovagene develops ultra-sensitive cell-free DNA assay SAN DIEGO, July 22, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) announces that results emerging from ongoing clinical studies have confirmed the broad applicability of Trovagene technology across a variety of cancer types, and the successful development of a molecular diagnostic test capable of detecting and quantifying oncogene mutations from a simple urine specimen. (Logo:...

2013-06-27 04:21:11

Presentation scheduled on June 27, 2013 at 9:20 a.m. ET in New York SAN DIEGO, June 27, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the OneMedForum Conference in New York on Thursday, June 27, 2013 at 9:20 a.m. Mr. Schuh and Chief Financial Officer Stephen Zaniboni will be available for one-on-one meetings during...

2013-06-03 04:21:20

Presentation scheduled on June 6, 2013 at 3:00 p.m. ET in New York SAN DIEGO, June 3, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the Jefferies 2013 Global Healthcare Conference in New York on Thursday, June 6, 2013 at 3:00 p.m. Mr. Schuh and Chief Financial Officer Stephen Zaniboni will be available for...

2013-04-01 16:24:36

SAN DIEGO, April 1, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three months and the year ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) Fourth Quarter 2012 Financial Results For the fourth quarter ended December 31, 2012, Trovagene reported a net loss of $6.3 million, or $0.43 per share, as compared to a net loss of $1.3 million, or $0.12 per...

2013-03-27 04:20:58

New, non-invasive molecular diagnostic test is easy, fast, and accurate SAN DIEGO, March 27, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), today announced the commercial availability of its urine-based HPV-HR (high-risk) assay, a molecular human papillomavirus (HPV) test. The non-invasive test is designed to accurately identify the presence or absence of 15 known high-risk HPV strains using proprietary DNA sequences. (Logo:...